Alcidion Group Limited (ALC) AI Stock Analysis

• Market Cap: AU$167.87M
• Dividend Yield: N/A
• Average Volume (3M): 1.29M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: -11.96%
• EPS Growth: 7.50%
• Country: AU
• Employees: 145
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Healthcare Information Services
• EPS (TTM): >-0.01
• Shares Outstanding: 1,342,952,600
• 10 Day Avg. Volume: 1,102,526
• 30 Day Avg. Volume: 1,288,627
• PEG Ratio: -0.67
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 921.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.12
• Price Target Upside: 0.00%
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 53 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

Alcidion Group Limited's stock score is primarily impacted by its financial performance, which is hampered by negative profitability and cash flow issues. Although technical indicators suggest positive short-term momentum, the stock's valuation remains unattractive due to a negative P/E ratio and lack of dividends. Improving operational efficiency and stabilizing revenue are critical for future prospects.

Alcidion Group Limited Business Overview & Revenue Model

Company Description

Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. The company offers Miya Precision, a consolidated fast healthcare interoperability resource (FHIR) based platform to deliver smart healthcare; Smartpage, a smartphone and web-based system for hospital communication and task management to address the requirements of clinical and non-clinical users; Patientrack, a real-time patient monitoring and risk screening solution; Silverlink, a patient administration system; and ExtraMed, a clinical and patient flow management software. It also provides product implementation, product support and maintenance, systems integration, and data analysis services. The company was formerly known as Alcidion Corporation Pty Ltd and changed its name to Alcidion Group Limited in December 2015. Alcidion Group Limited was founded in 2000 and is headquartered in South Yarra, Australia.

How the Company Makes Money

Alcidion Group Limited generates revenue primarily through the sale of its software solutions and related services to healthcare organizations. The company's key revenue streams include licensing fees for its platforms, such as Miya Precision and Smartpage, as well as ongoing maintenance and support services. Additionally, Alcidion offers implementation and consulting services to assist healthcare providers in integrating its solutions into their existing systems. Significant partnerships with healthcare institutions and technology companies also play a role in expanding its market reach and driving sales. By focusing on digital transformation in healthcare, Alcidion positions itself as a critical partner in the industry, contributing to its financial growth.

Alcidion Group Limited Financial Statement Overview

Summary

Alcidion Group Limited faces challenges with profitability and cash generation, despite a strong equity base and low leverage. The company needs to improve operational efficiency and stabilize revenue growth to enhance financial stability. Continued losses and negative cash flows are areas of concern.

Income Statement

The company has shown volatility in its revenue with a decrease from the previous year. Gross profit margin is strong at approximately 86.1%, but net profit margin is deeply negative due to substantial losses. EBIT and EBITDA margins are also negative, indicating operational inefficiencies and high operating costs.

Balance Sheet

The company maintains a strong equity position with an equity ratio of approximately 75.9%. However, consistent losses have led to a negative return on equity. The debt-to-equity ratio is low at 0.02, indicating minimal leverage which poses less financial risk.

Cash Flow

Cash flow from operations is negative, and free cash flow has decreased from the previous year, indicating challenges in generating cash from core activities. The free cash flow to net income ratio is negative, reflecting operational difficulties.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	37.06M	40.40M	34.35M	25.88M	18.55M
Gross Profit	31.92M	1.25M	3.29M	3.52M	401.23K
EBITDA	-4.50M	-1.43M	-1.58M	-474.00K	-3.77M
Net Income	-8.42M	-3.62M	-4.41M	-2.24M	-3.08M
Balance Sheet
Total Assets	114.46M	120.68M	128.35M	58.38M	39.43M
Cash, Cash Equivalents and Short-Term Investments	11.80M	14.64M	17.34M	25.03M	15.95M
Total Debt	1.70M	2.15M	2.48M	181.00K	315.85K
Total Liabilities	27.52M	30.52M	34.40M	13.16M	9.70M
Stockholders Equity	86.94M	90.17M	93.95M	45.22M	29.74M
Cash Flow
Free Cash Flow	-7.18M	-285.00K	685.00K	1.23M	-2.14M
Operating Cash Flow	-7.13M	169.00K	996.00K	1.54M	-2.02M
Investing Cash Flow	-53.00K	-3.14M	-59.74M	-9.84M	-362.04K
Financing Cash Flow	4.34M	-616.00K	51.33M	17.23M	15.16M

Alcidion Group Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALC, the sentiment is Positive. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.10, and above the 200-day MA of 0.08, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 66.41 is Neutral, neither overbought nor oversold. The STOCH value of 71.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ALC.

Alcidion Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	€6.48B	19.09	-1.30%	2.17%	-0.15%	-41.88%
ALC	53 Neutral	AU$167.87M	―	-5.63%	―	-11.96%	7.50%
ONVVF	―	$122.70M	―		―	―	―
TDMMF	―	$66.76M	―	-9.88%	―	―	―
PCK	55 Neutral	AU$73.68M	―	-457.46%	―	21.93%	10.34%
BMT	52 Neutral	AU$75.55M	―	-11.80%	―	14.56%	13.36%
SHG	48 Neutral	AU$95.03M	―		―	―	―

Alcidion Group Limited Corporate Events

Alcidion Group Achieves Record Cash Flow and Expands Key Contracts in Q4 FY25

Alcidion Group Limited reported a record-breaking quarter with a positive operating cash flow of $7.4 million, marking the highest in the company’s history. The company achieved significant growth in new sales and contract expansions, notably with North Cumbria Integrated Care NHS Trust, which increased the total contract value to over $39 million. Alcidion ended the fiscal year with a cash balance of $17.7 million and no debt, demonstrating a strong financial position. The company’s continued expansion and deployment of its Miya Precision platform underscore its long-term value proposition and market momentum.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Group to Release Q4 FY25 Results and Host Investor Webcast

Alcidion Group Limited announced it will release its Q4 FY25 financial results and host an investor webcast on July 24, 2025. The webcast will feature discussions by the Group Managing Director and CEO, Kate Quirke, and CFO, Matthew Gepp, on the company’s operational and commercial highlights for the quarter. This announcement underscores Alcidion’s commitment to transparency with its stakeholders and its strategic focus on expanding its influence in the global healthcare market.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Group Boosts FY25 Financial Guidance Amid Strong Performance

Alcidion Group Limited has upgraded its financial guidance for the fiscal year ending June 2025, expecting EBITDA to exceed $4.5 million, up from the previous forecast of over $3.0 million. This improvement is attributed to smaller contract upgrades, extensions, diligent cost management, and favorable foreign exchange movements. The company’s Miya platform continues to gain traction, leading to increased customer engagement and new opportunities, reinforcing Alcidion’s long-term value proposition and ability to address critical challenges in global hospital systems.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Group Limited Announces Cessation of Performance Rights

Alcidion Group Limited announced the cessation of 206,458 performance rights due to the lapse of conditional rights that were not satisfied by the specified date. This development may impact the company’s capital structure and could have implications for stakeholders as it reflects on the company’s performance metrics and strategic objectives.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.

Alcidion Announces Board Change with Director Departure

Alcidion Group Limited has announced a change in its board of directors, with Victoria Weekes ceasing to be a director as of May 30, 2025. This update, in compliance with ASX Listing Rule 3.19A.3, is part of the company’s ongoing corporate governance and may impact its strategic direction as it continues to expand its healthcare technology services globally.

The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.